Investment in Natural Rf Life Sciences Inc.
managed by CEO Dr. Jacqueline
Shan
TSX Venture: QPT
EDMONTON, May 4, 2017 /CNW/ - Quest PharmaTech Inc.
(TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company
developing and commercializing products to improve the quality of
life, today announced that it is making a $500,000 cash investment to acquire 32% of the
outstanding common stock of Natural Rf Life Sciences Inc., a
private company developing and marketing science based, clinically
tested, natural heath products. Natural Rf Life Sciences Inc. was
founded and is managed by Dr. Jacqueline
Shan, co-creator of Canada's number one colds and flu brand,
COLD-FX™. Dr. Shan is prominent throughout the natural health
products industry as the scientist leading the development of
higher standards for evidence based natural health products, and
bringing such products to market using the scientific standards and
techniques long established within the pharmaceutical industry.
The first launched product, Allergy-Rf™, is the only natural
health product clinically proven in a human study to provide
effective, fast acting, multifunctional respiratory relief from
seasonal and environmental allergies. Most OTC anti-allergy
products block the activity of histamines after they have been
released from mast cells during an allergic attack. Allergy-Rf™ may
proactively work to prevent the allergens from attacking the body
and subsequent releasing of histamines, thereby greatly reducing an
allergic response. The efficacy and safety of Allergy-Rf™ has been
confirmed in a double-blind, placebo-controlled trial.
"We are excited to work with Quest on this clinically tested
natural health product," said Dr. Jacqueline Shan. "Allergy-Rf™ is a 100%
naturally sourced alternative to OTC drug products, and is an
excellent option for people who suffer from seasonal and
environmental allergies."
"We are pleased to expand our consumer health product pipeline
beyond Bellus Skin™ Rejuvenation Serum (www.bellusskin.com) and
provide consumers with more choices based on scientifically
developed, clinically proven natural health products," said Dr.
Madi R. Madiyalakan, Chief Executive
Officer for Quest. "OTC natural health products represent a
multibillion dollar market, but most products are unproven in terms
of quality or efficacy. We believe our products can distinguish
themselves from others and enable us to gain the trust of our
customers."
About Natural Rf Life Sciences Inc.
Natural Rf Life Sciences Inc. is a private Canadian company that is
focused on developing evidence - based natural therapeutics and
building consumer health brands. Natural Rf is currently launching
a Health Canada approved (NPN # 80053988), clinically proven
natural health product, Allergy-Rf™, previously known as
Allergy-FX™, in health food and pharmacy stores across Canada. The company has a pipeline of natural
health products and plans to launch more health condition-specific
Rf brands in women's health, joint health, stress, pain and
cardiovascular health. Natural Rf Life Sciences is also developing
its international markets through strategic partnership and
distribution agreements with international consumer health and
bioscience companies. For more information, please visit
www.AllergyRf.com
About Quest PharmaTech Inc.
Quest PharmaTech is a
publicly traded, Canadian based pharmaceutical company developing
products to improve the quality of life. The Company through its
subsidiary, OncoQuest is developing antibody based
immunotherapeutic products for cancer. In addition, the Company
owns the Photodynamic Therapy technology for oncology and
dermatology applications, licensed to BioCeltran Co., Ltd., a Korea
based company (Bioceltran). Quest has an ownership interest
in Bioceltran which is focused on SP Technology™ for transdermal
delivery of drugs and photosensitizers for pharmaceutical and
cosmetic purposes. Quest also markets consumer health products
worldwide, including Bellus Skin™ serum, a premium anti-wrinkle
skin care product licensed from Korea. Quest is also
developing an antibody licensed from University of Nebraska, Mab AR 9.6 against
truncated O-glycan on MUC16, for targeted cancer therapy
applications.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE Quest PharmaTech Inc.